论文部分内容阅读
Viekira Pak是由帕利瑞韦(paritaprevir)、奥毕他韦(ombitasvir)、达萨布韦(dasabuvir)和利托那韦组成的复方制剂。由于本品能同时抑制NS3/4A、NS5A、NS5B四个非结构蛋白,对于丙型肝炎病毒(HCV)繁殖周期进行了全覆盖,从而增加抑制HCV能力,减少其耐药性的概率。临床试验证明对于HCV基因Ⅰa、Ⅰb型患者都有疗效,无论他们是初次治疗、还是复治、或者有无肝硬化并发症疗效都很明显。但是对于基因Ⅰa型、有肝硬化并发症的Ⅰb患者,本品还需要与利巴韦林合用,才能产生好的疗效,这可能会限制本品的应用。
Viekira Pak is a combination of paritaprevir, ombitasvir, dasabuvir and ritonavir. As the product can simultaneously inhibit the NS3 / 4A, NS5A, NS5B four non-structural proteins, the full coverage of the hepatitis C virus (HCV) breeding cycle, thereby increasing the inhibition of HCV ability and reduce the probability of its resistance. Clinical trials have shown efficacy in patients with HCV genotypes Ia and Ib, regardless of whether they are first-time or retreatment, or whether there are complications of cirrhosis. But for genotype Ⅰ a, Ⅰ b patients with complications of liver cirrhosis, this product also need to be combined with ribavirin, in order to produce good effect, which may limit the application of this product.